Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following He...(Cardium Therapeutics and InnerCool Thera...),Health

Date:4/15/2008

Cardium Therapeutics and InnerCool Therapies. "To achieve cooling rates that were shown in the study to be beneficial requires the ability to lower core body temperature to 35 degrees Celsius or less within a time window as short as about 15 minutes while patients are awake. InnerCool's Accutrol catheter not only provides rapid cooling but the unique integrated temperature sensor enables fast and precise feedback of core body temperature, compared to delayed temperature feedback using peripheral temperature probes. Speed and precision are performance features that can be especially critical in acute care settings such as those following a heart attack."

Rapid & Early Cooling Heart Attack Preclinical Study Results

This study was designed to further investigate the therapeutic potential of early and rapid hypothermia to preserve heart tissue following a heart attack. Using a closed-chest porcine heart attack model in which the coronary artery supplying the heart muscle was initially blocked and later reopened, as occurs in patients after a heart attack or acute myocardial infarction (MI), the investigators evaluated the effects of rapid cooling to a target temperature of 33 degrees Celsius to 35 degrees Celsius on myocardial infarct size as assessed by cardiac magnetic resonance imaging (MRI). Rapid hypothermia, induced by the infusion of one liter of cold saline in combination with InnerCool's endovascular catheter-based temperature modulation system, initiated either prior to or after restoration of blood flow (reperfusion), was compared to a normal core body temperature of 38 degrees Celsius throughout the procedure.

The data showed that early rapid cooling substantially reduced the damage to heart muscle that typically follows a heart attack and reperfusion. In particular, cooling prior to reperfusion reduced overall myocardial infarct size by 43% compared to hypothermia after reperfusion (p<0.05), and by 39% compared to normothermia (p<0.05)
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias